Breaking News, Financial News

Wyeth 3Q

Wyeth

3Q Revenues: $5.6 billion (+9%)

3Q Earnings: $1.1 billion (flat)

YTD Revenues: $16.6 billion (+10%)

YTD Earnings: $3.6 billion (+8%)

Comments: 3Q pharma revenues were up 10% to $4.7 billion, driven by a 24% boost in sales of Prevnar vaccine to $634 million and a 39% rise in ex-NA sales of Enbrel to $527 million. Top-seller Effexor posted a 4% increasse to $958 million. Earnings were impaired by a $117 million charge related to Wyeth’s ongoing restructuring.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters